Literature DB >> 28615303

Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.

Hung-Yu Sun1, Pin-Nan Cheng2, Chiung-Ying Tseng1, Wei-Jen Tsai1, Yen-Cheng Chiu2, Kung-Chia Young1,3,4.   

Abstract

OBJECTIVE: Lipid homoeostasis is disturbed in patients with HCV infection. Direct-acting antiviral agent (DAA) treatment eradicates chronic HCV viraemia, but the dynamics of lipid components remain elusive. This study investigates the clinical manifestation and mechanistic relevance of plasma triglyceride (TG), cholesterol (Chol), lipoproteins and apolipoproteins (apos) after DAA treatment.
DESIGN: Twenty-four patients with chronic genotype 1 (GT1) HCV treated with elbasvir/grazoprevir or ledipasvir/sofosbuvir for 12 weeks, and followed-up thereafter, were recruited. Their TG, Chol, apoAI and apoB levels were quantified in plasma samples and individually fractionated lipoprotein of various classes. Liver fibrosis was evaluated using the FIB-4 Score. The TG and Chol loading capacities were calculated with normalisation to apoB, which represents per very low density lipoprotein (VLDL) and LDL particle unit
RESULTS: DAA treatment achieved a sustained virological response rate of 91.7% and reduced the FIB-4 Score. Relative to the baseline, the plasma TG level was reduced but the Chol level increased gradually. Plasma apoB levels and apoB/apoAI ratio were transiently downregulated as early as the first 4 weeks of treatment. The TG and Chol loading capacities in VLDL were elevated by ~20% during the period of DAA treatment and had steadily increased by 100% at follow-up. Furthermore, the TG-to-Chol ratio in VLDL was increased, while the ratio in LDL was reduced, indicating an efficient catabolism.
CONCLUSION: The DAA treatment of patients with chronic hepatitis C might lead to efficient HCV eradication and hepatic improvement concomitantly evolving with favouring lipoprotein/apo metabolisms. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  apolipoprotein; direct-acting antiviral agent; hepatitis C virus; lipoprotein metabolism

Mesh:

Substances:

Year:  2017        PMID: 28615303     DOI: 10.1136/gutjnl-2017-313832

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   31.793


  13 in total

1.  Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol.

Authors:  Yi-Kai Wang; Ying-Wen Wang; Chia-Ling Lu; Yi-Hsiang Huang; Ming-Chih Hou; Yuh-Lih Chang; Wei-Ping Lee; Keng-Hsin Lan
Journal:  Sci Rep       Date:  2022-06-15       Impact factor: 4.996

2.  Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?

Authors:  Andre J Jeyarajan; Raymond T Chung
Journal:  J Infect Dis       Date:  2020-11-27       Impact factor: 5.226

3.  Clinical effects of simvastatin in chronic hepatitis C patients receiving sofosbuvir/daclatasvir combination. A randomized, placebo-controlled, double-blinded study.

Authors:  Hossam Z Mohamed; Nagwa A Sabri; Hossam M Zaki; Sara M Shaheen
Journal:  Clin Exp Hepatol       Date:  2020-05-25

4.  Augmenting central arterial stiffness following eradication of HCV by direct acting antivirals in advanced fibrosis patients.

Authors:  Pin-Nan Cheng; Ju-Yi Chen; Yen-Cheng Chiu; Hung-Chih Chiu; Liang-Miin Tsai
Journal:  Sci Rep       Date:  2019-02-05       Impact factor: 4.379

Review 5.  Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response.

Authors:  Sara Cuesta-Sancho; Mercedes Márquez-Coello; Francisco Illanes-Álvarez; Denisse Márquez-Ruiz; Ana Arizcorreta; Fátima Galán-Sánchez; Natalia Montiel; Manuel Rodriguez-Iglesias; José-Antonio Girón-González
Journal:  World J Hepatol       Date:  2022-01-27

6.  Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study.

Authors:  Heng Lee; Rong-Nan Chien; Li-Heng Pao; Chia-Jung Kuo; Po-Han Huang; Ming-Ling Chang
Journal:  Cells       Date:  2021-10-28       Impact factor: 6.600

Review 7.  Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis.

Authors:  Xiaolin Wang; Qing Xie
Journal:  J Clin Transl Hepatol       Date:  2021-10-08

8.  Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis.

Authors:  Rosanna Villani; Francesca Di Cosimo; Antonino Davide Romano; Moris Sangineto; Gaetano Serviddio
Journal:  Sci Rep       Date:  2021-07-06       Impact factor: 4.379

Review 9.  Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy.

Authors:  Sylvia Drazilova; Jakub Gazda; Martin Janicko; Peter Jarcuska
Journal:  Can J Gastroenterol Hepatol       Date:  2018-08-13

Review 10.  Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges.

Authors:  Haiyan Zeng; Lei Li; Zhouhua Hou; Yapeng Zhang; Zhongxiang Tang; Shuiping Liu
Journal:  Int J Med Sci       Date:  2020-03-15       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.